Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of hypertension
14 evidence topics · 16 sources
Hypertension prevalence: NHANES August 2021 to August 2023
Awareness, treatment, and control: NHANES August 2021 to August 2023
Hypertension prevalence, uncontrolled blood pressure, and race: CDC
Treated but uncontrolled hypertension: Million Hearts cascade, NHANES 2017 to 2020
Blood pressure control trends: NHANES 1999 to 2018
“In this serial cross-sectional study that included 18 262 US adults aged 18 years or older with hypertension, with data weighted to be representative of the US population, the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among adults taking antihypertensive medication, the age-adjusted estimated proportion with controlled BP increased from 53.4% (95% CI, 49.0%-57.9%) in 1999-2000 to 68.3% (95% CI, 65.9%-70.8%) in 2007-2008, remained stable and was 72.2% (95% CI, 68.6%-75.8%) in 2013-2014, and then declined to 64.8% (95% CI, 61.3%-68.3%) in 2017-2018 (part B in the Figure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled hypertension above goal: ICER
Apparent treatment-resistant hypertension: NHANES 2003 to 2020
“Apparent treatment resistant hypertension (aTRH) was defined as patients on a diuretic, either with a systolic blood pressure (BP) ≥130 or diastolic BP ≥80 mmHg while on 3 medications or those on ≥ 4 medications regardless of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 24,579 adults with HTN, 1,939 had aTRH (42.4% male, 19.9% Black), corresponding to a weighted total of 6,989,821 US patients. Among hypertensive adults, the prevalence of aTRH was 6.41% (95% CI 5.97-6.88%) and remained stable over time. Over the study duration, aTRH prevalence among adults on treatment decreased from 17.7% to 12.6%. The overall prevalence of hypertension rose from 50.1% to 54.0%, while the prevalence of uncontrolled BP decreased from 75.0% to 68.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“aTRH was most strongly associated with older patients, those of Black race, higher BMI, and more advanced cardiovascular comorbidities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Apparent treatment-resistant hypertension: NHANES 2009 to 2014, 2008 and 2018 AHA definitions
“The prevalence of aTRH was 17.7% and 19.7% according to the 2008 and 2018 Scientific Statement definitions, respectively (Δ=2.0%; 95%CI 1.5%, 2.7%). Overall, 10.3 million US adults had aTRH according to the 2018 Scientific Statement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension prevalence: guideline and scientific statement estimates
“Among treated adults with hypertension, prevalent aTRH occurs in ≈12% to 15% of population-based” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and 15% to 18% of clinic-based reports.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Controlled and uncontrolled resistant hypertension: Kaiser Permanente Southern California
“Resistant hypertension was identified in 60,327 (12.8%) individuals of whom 23,104 met our criteria for cRH and 37,223 met our criteria for uRH. Thus, uRH accounted for 61.7% of the resistant hypertension population and 7.9% of all hypertensive individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled and resistant hypertension: US real-world patient funnel, Optum Market Clarity, 2018 to 2025
Global resistant hypertension prevalence: meta-analysis of 91 studies
“In the general, population of treated patients with hypertension, the prevalence of true-resistant, apparent treatment-resistant and pseudo-resistant hypertension were 10.3% (95% CI 7.6% to 13.2%), 14.7% (95% CI 13.1% to 16.3%) and 10.3% (95% CI 6.0% to 15.5%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global hypertension prevalence, treatment, and control
“The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote